Peringatan Keamanan

Patients experiencing an overdose may present with hypocalcemia, hypophosphatemia, upset stomach, dyspepsia, esophagitis, and uclers.L13805,L13808 Oral overdose can be managed by giving patients milk or antacids to bind excess unabsorbed ibandronate.L13805 Overdoses can be managed by providing intravenous electrolytes and dialysis is not expected to remove excess drug from serum.L13805,L13808

Ibandronate

DB00710

small molecule approved investigational

Deskripsi

Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid.A203111,A203138 It is used to prevent and treat postmenopausal osteoporosis.L13805,L13808 Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.A203138

Ibandronate was granted FDA approval on 16 May 2003.L13805

Struktur Molekul 2D

Berat 319.2289
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of ibandronate in postmenopausal women ranges from 37-157 hours.[L13805,L13808]
Volume Distribusi The apparent terminal volume of distribution of ibandronate is 90-368L in headlthy subjects and 103L in postmenopausal women with osteopenia.[A203153,L13805,L13808]
Klirens (Clearance) The total clearance of ibandronate is 84-160mL/min.[L13805,L13808]

Absorpsi

Oral ibandronate is 0.63% bioavailable.A203153 In a study of healthy males, a 10mg oral dose had a Tmax of 1.1±0.6h and a Cmax of 4.1±2.6ng/mL.A203162 The Tmax is approximately 1 hour, while Cmax varies depending on dose.A203162 A 2mg intravenous dose of ibandronate has an AUC of 316ng\*h/mL, a 4mg intravenous dose of ibandronate has an AUC of 581ng\*h/mL, and a 6mg intravenous dose of ibandronate has an AUC of 908ng\*h/mL.A203159

Metabolisme

Ibanronate is not metabolized in humans.L13805,L13808

Rute Eliminasi

Ibandronate is predominantly eliminated in the urine and the unabsorbed drug is eliminated unchanged in the feces.A203153,L13805,L13808

Interaksi Makanan

2 Data
  • 1. Take on an empty stomach.
  • 2. Take with a full glass of water. Do not take this medication with other liquids.

Interaksi Obat

762 Data
Deferasirox The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Ibandronate is combined with Deferasirox.
Bevacizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Ibandronate.
Lenalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Ibandronate.
Thalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Ibandronate.
Sunitinib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Ibandronate.
Ranibizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Ibandronate.
Fumagillin The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Ibandronate.
Resveratrol The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Ibandronate.
Halofuginone The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Ibandronate.
Anecortave acetate The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave acetate is combined with Ibandronate.
Endostatin The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostatin is combined with Ibandronate.
Semaxanib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Semaxanib is combined with Ibandronate.
Squalamine The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Ibandronate.
Pazopanib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Ibandronate.
Volociximab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Volociximab is combined with Ibandronate.
TNP-470 The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when TNP-470 is combined with Ibandronate.
Pomalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Ibandronate.
Roquinimex The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Ibandronate.
Endostar The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostar is combined with Ibandronate.
Trebananib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Ibandronate.
Anecortave The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Ibandronate.
Beloranib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Beloranib is combined with Ibandronate.
Brolucizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Ibandronate.
Pantoprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.
Omeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.
Lansoprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.
Esomeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole.
Rabeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.
Dexlansoprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole.
Dexrabeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexrabeprazole.
Ilaprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Ilaprazole.
Icosapent The risk or severity of gastrointestinal bleeding can be increased when Icosapent is combined with Ibandronate.
Mesalazine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mesalazine is combined with Ibandronate.
Indomethacin The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Ibandronate.
Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Ibandronate.
Ketorolac The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Ibandronate.
Tenoxicam The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Ibandronate.
Celecoxib The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Ibandronate.
Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Ibandronate.
Rofecoxib The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Ibandronate.
Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Ibandronate.
Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Ibandronate.
Valdecoxib The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Ibandronate.
Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Ibandronate.
Sulindac The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Ibandronate.
Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Ibandronate.
Etodolac The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Ibandronate.
Mefenamic acid The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Ibandronate.
Naproxen The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Ibandronate.
Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Ibandronate.
Phenylbutazone The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Ibandronate.
Meloxicam The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Ibandronate.
Carprofen The risk or severity of gastrointestinal bleeding can be increased when Carprofen is combined with Ibandronate.
Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Ibandronate.
Salicylic acid The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Ibandronate.
Meclofenamic acid The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Ibandronate.
Acetylsalicylic acid The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Ibandronate.
Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Ibandronate.
Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Ibandronate.
Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Ibandronate.
Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Ibandronate.
Olsalazine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Olsalazine is combined with Ibandronate.
Lumiracoxib The risk or severity of gastrointestinal bleeding can be increased when Lumiracoxib is combined with Ibandronate.
Magnesium salicylate The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Ibandronate.
Salsalate The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Ibandronate.
Choline magnesium trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Choline magnesium trisalicylate is combined with Ibandronate.
Antrafenine The risk or severity of gastrointestinal bleeding can be increased when Antrafenine is combined with Ibandronate.
Aminophenazone The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Ibandronate.
Antipyrine The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Ibandronate.
Tiaprofenic acid The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Ibandronate.
Etoricoxib The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Ibandronate.
Taxifolin The risk or severity of gastrointestinal bleeding can be increased when Taxifolin is combined with Ibandronate.
Oxyphenbutazone The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Ibandronate.
Licofelone The risk or severity of gastrointestinal bleeding can be increased when Licofelone is combined with Ibandronate.
Nimesulide The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Ibandronate.
Benoxaprofen The risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Ibandronate.
Metamizole The risk or severity of nephrotoxicity and hypocalcemia can be increased when Metamizole is combined with Ibandronate.
Zomepirac The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Ibandronate.
Cimicoxib The risk or severity of gastrointestinal bleeding can be increased when Cimicoxib is combined with Ibandronate.
Lornoxicam The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Ibandronate.
Aceclofenac The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Ibandronate.
Zaltoprofen The risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Ibandronate.
Azapropazone The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Ibandronate.
Parecoxib The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Ibandronate.
Salicylamide The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Ibandronate.
Kebuzone The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Ibandronate.
Isoxicam The risk or severity of gastrointestinal bleeding can be increased when Isoxicam is combined with Ibandronate.
Indoprofen The risk or severity of gastrointestinal bleeding can be increased when Indoprofen is combined with Ibandronate.
Ibuproxam The risk or severity of gastrointestinal bleeding can be increased when Ibuproxam is combined with Ibandronate.
Floctafenine The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Ibandronate.
Fenbufen The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Ibandronate.
Etofenamate The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Ibandronate.
Epirizole The risk or severity of gastrointestinal bleeding can be increased when Epirizole is combined with Ibandronate.
Benzydamine The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Ibandronate.
Dexibuprofen The risk or severity of gastrointestinal bleeding can be increased when Dexibuprofen is combined with Ibandronate.
Dexketoprofen The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Ibandronate.
Droxicam The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Ibandronate.
Tolfenamic acid The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic acid is combined with Ibandronate.
Firocoxib The risk or severity of gastrointestinal bleeding can be increased when Firocoxib is combined with Ibandronate.
Clonixin The risk or severity of gastrointestinal bleeding can be increased when Clonixin is combined with Ibandronate.

Target Protein

Hydroxylapatite
Geranylgeranyl pyrophosphate synthase GGPS1
Farnesyl pyrophosphate synthase FDPS

Referensi & Sumber

Synthesis reference: Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, "Solid and crystalline ibandronate sodium and processes for preparation thereof." U.S. Patent US20070179119, issued August 02, 2007.
Artikel (PubMed)
  • PMID: 30650219
    Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG: Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28.
  • PMID: 8266826
    Monier-Faugere MC, Friedler RM, Bauss F, Malluche HH: A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res. 1993 Nov;8(11):1345-55. doi: 10.1002/jbmr.5650081109.
  • PMID: 18442135
    Cao R, Chen CK, Guo RT, Wang AH, Oldfield E: Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases. Proteins. 2008 Nov 1;73(2):431-9. doi: 10.1002/prot.22066.
  • PMID: 11389070
    Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001 Jun 1;61(11):4418-24.
  • PMID: 18214569
    Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8.
  • PMID: 9145236
    Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya K, Abe M, Yuda Y, Konno F, Barbier A, Suda T: Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 1997 May;20(5):399-404.
  • PMID: 23044853
    Miwa A, Takezako N, Hayakawa H, Hayakawa M, Tominaga S, Yanagisawa K: YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation. Am J Hematol. 2012 Dec;87(12):1084-8. doi: 10.1002/ajh.23328. Epub 2012 Oct 9.
  • PMID: 18624681
    Reginster JY, Neuprez A, Bruyere O: Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):941-51. doi: 10.1517/17425255.4.7.941.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 65 • International brands: 1
Produk
  • Bondenza
    Tablet, film coated • 150 mg • Oral • EU
  • Bondenza
    Tablet, film coated • 150 mg • Oral • EU
  • Bondenza
    Injection, solution • 3 mg • Intravenous • EU
  • Bondenza
    Injection, solution • 3 mg • Intravenous • EU
  • Bondronat
    Liquid • 1 mg / mL • Intravenous • Canada • Approved
  • Bondronat
    Injection, solution, concentrate • 2 mg • Intravenous • EU • Approved
  • Bondronat
    Tablet, film coated • 50 mg • Oral • EU • Approved
  • Bondronat
    Tablet, film coated • 50 mg • Oral • EU • Approved
Menampilkan 8 dari 65 produk.
International Brands
  • ADRONiL

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul